Cargando…

LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A

BACKGROUND: Prophylactic treatment is the gold standard in the treatment of patients with haemophilia. Prophylaxis with extended half‐life (EHL) treatment has shown long‐term safety and efficacy in patients with haemophilia. AIM: To evaluate the efficacy of prophylaxis with EHL treatment in the freq...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuesta‐Barriuso, Rubén, Pérez‐Llanes, Raúl, Donoso‐Úbeda, Elena, Ucero‐Lozano, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541876/
https://www.ncbi.nlm.nih.gov/pubmed/35561281
http://dx.doi.org/10.1111/hae.14592
_version_ 1784804022890266624
author Cuesta‐Barriuso, Rubén
Pérez‐Llanes, Raúl
Donoso‐Úbeda, Elena
Ucero‐Lozano, Roberto
author_facet Cuesta‐Barriuso, Rubén
Pérez‐Llanes, Raúl
Donoso‐Úbeda, Elena
Ucero‐Lozano, Roberto
author_sort Cuesta‐Barriuso, Rubén
collection PubMed
description BACKGROUND: Prophylactic treatment is the gold standard in the treatment of patients with haemophilia. Prophylaxis with extended half‐life (EHL) treatment has shown long‐term safety and efficacy in patients with haemophilia. AIM: To evaluate the efficacy of prophylaxis with EHL treatment in the frequency of haemarthrosis and musculoskeletal health in adult patients with severe haemophilia A. METHODS: Prospective cohort study. Forty‐six patients with severe haemophilia A were recruited. The frequency of haemarthrosis (self‐reports), joint condition (Haemophilia Joint Health Score), pain intensity (visual analogue scale), range of motion (goniometry), and strength (dynamometry) and muscle activation (surface electromyography) were evaluated. Three assessments were carried out: at baseline (T0), at 6 months (T1) and at 12 months following treatment (T2). RESULTS: There were significant changes in the within‐subject effect in the frequency of haemarthrosis in elbow (F(1.05;96.20) = 3.95; P < .001) and knee (F(1.73;157.99) = 9.96; P < .001). Significant within‐subject effect in elbow pain intensity (F(2;182) = 63.51; P < .001) was found. The mean values of the frequency haemarthrosis in elbow (from .66±1.01 to .04±.20) and knees (from .55±.68 to .33±.53) decrease after the period study. The intensity of elbow pain and (from 3.08±1.69 to 2.67±1.73), decrease after the 12‐month follow‐up period. CONCLUSIONS: Prophylaxis with extended half‐life treatment reduces the frequency of haemarthrosis in elbow and knee in adult patients with haemophilia. EHL treatment reduces the intensity of elbow pain in patients with haemophilic arthropathy.
format Online
Article
Text
id pubmed-9541876
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95418762022-10-14 LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A Cuesta‐Barriuso, Rubén Pérez‐Llanes, Raúl Donoso‐Úbeda, Elena Ucero‐Lozano, Roberto Haemophilia Original Articles BACKGROUND: Prophylactic treatment is the gold standard in the treatment of patients with haemophilia. Prophylaxis with extended half‐life (EHL) treatment has shown long‐term safety and efficacy in patients with haemophilia. AIM: To evaluate the efficacy of prophylaxis with EHL treatment in the frequency of haemarthrosis and musculoskeletal health in adult patients with severe haemophilia A. METHODS: Prospective cohort study. Forty‐six patients with severe haemophilia A were recruited. The frequency of haemarthrosis (self‐reports), joint condition (Haemophilia Joint Health Score), pain intensity (visual analogue scale), range of motion (goniometry), and strength (dynamometry) and muscle activation (surface electromyography) were evaluated. Three assessments were carried out: at baseline (T0), at 6 months (T1) and at 12 months following treatment (T2). RESULTS: There were significant changes in the within‐subject effect in the frequency of haemarthrosis in elbow (F(1.05;96.20) = 3.95; P < .001) and knee (F(1.73;157.99) = 9.96; P < .001). Significant within‐subject effect in elbow pain intensity (F(2;182) = 63.51; P < .001) was found. The mean values of the frequency haemarthrosis in elbow (from .66±1.01 to .04±.20) and knees (from .55±.68 to .33±.53) decrease after the period study. The intensity of elbow pain and (from 3.08±1.69 to 2.67±1.73), decrease after the 12‐month follow‐up period. CONCLUSIONS: Prophylaxis with extended half‐life treatment reduces the frequency of haemarthrosis in elbow and knee in adult patients with haemophilia. EHL treatment reduces the intensity of elbow pain in patients with haemophilic arthropathy. John Wiley and Sons Inc. 2022-05-13 2022-09 /pmc/articles/PMC9541876/ /pubmed/35561281 http://dx.doi.org/10.1111/hae.14592 Text en © 2022 The Authors. Haemophilia published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Cuesta‐Barriuso, Rubén
Pérez‐Llanes, Raúl
Donoso‐Úbeda, Elena
Ucero‐Lozano, Roberto
LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A
title LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A
title_full LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A
title_fullStr LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A
title_full_unstemmed LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A
title_short LongHest project: A prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia A
title_sort longhest project: a prospective, observational study of extended half‐life treatment in the musculoskeletal health of patients with severe haemophilia a
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541876/
https://www.ncbi.nlm.nih.gov/pubmed/35561281
http://dx.doi.org/10.1111/hae.14592
work_keys_str_mv AT cuestabarriusoruben longhestprojectaprospectiveobservationalstudyofextendedhalflifetreatmentinthemusculoskeletalhealthofpatientswithseverehaemophiliaa
AT perezllanesraul longhestprojectaprospectiveobservationalstudyofextendedhalflifetreatmentinthemusculoskeletalhealthofpatientswithseverehaemophiliaa
AT donosoubedaelena longhestprojectaprospectiveobservationalstudyofextendedhalflifetreatmentinthemusculoskeletalhealthofpatientswithseverehaemophiliaa
AT ucerolozanoroberto longhestprojectaprospectiveobservationalstudyofextendedhalflifetreatmentinthemusculoskeletalhealthofpatientswithseverehaemophiliaa